E-LIB Suche - Ergebnisse für: Koleva-Kolarova, Rositsa

1

Predicting the future risk of lung cancer: development, and..:

Liao, Weiqi ; Coupland, Carol A C ; Burchardt, Judith...
The Lancet Respiratory Medicine. 11 (2023) 8 - p. 685-697 , 2023

Link: https://doi.org/10.1016/..

2

Cost–effectiveness of extendedDPYDtesting before fluoropyri..:

Koleva-Kolarova, Rositsa ; Vellekoop, Heleen ; Huygens, Simone...
Personalized Medicine. 20 (2023) 4 - p. 339-355 , 2023

Link: https://doi.org/10.2217/..

3

Lessons Learned from the Application of the HEcoPerMed Guid..:

Nagy, Balázs ; Zelei, Tamás ; Vellekoop, Heleen...
Personalized Medicine. 20 (2023) 4 - p. 401-411 , 2023

Link: https://doi.org/10.2217/..

4

Cost–effectiveness and budget impact analysis of screening ..:

Szilberhorn, László ; Zelei, Tamás ; Vellekoop, Heleen...
Personalized Medicine. 20 (2023) 4 - p. 387-399 , 2023

Link: https://doi.org/10.2217/..

5

Cost–effectiveness of AlternativeNTRKTesting Strategies in ..:

Vellekoop, Heleen ; Huygens, Simone ; Versteegh, Matthijs...
Personalized Medicine. 20 (2023) 4 - p. 321-338 , 2023

Link: https://doi.org/10.2217/..

6

Budget Impact and Transferability of Cost–effectiveness ofD..:

Koleva-Kolarova, Rositsa ; Vellekoop, Heleen ; Huygens, Simone...
Personalized Medicine. 20 (2023) 4 - p. 357-374 , 2023

Link: https://doi.org/10.2217/..

7

Cost–effectiveness of Genetic-Based Screening Strategies fo..:

Kovács, Gábor ; Nagy, Dávid ; Szilberhorn, László...
Personalized Medicine. 20 (2023) 4 - p. 375-385 , 2023

Link: https://doi.org/10.2217/..

8

Financial incentives to promote personalized medicine in Eu..:

Koleva-Kolarova, Rositsa ; Szilberhorn, László ; Zelei, Tamás...
Personalized Medicine. 20 (2023) 4 - p. 305-319 , 2023

Link: https://doi.org/10.2217/..

9

Cost-Effectiveness Analysis of Treating Patients With NTRK-..:

Huygens, Simone ; Vellekoop, Heleen ; Versteegh, Matthijs...
Value in Health. 26 (2023) 2 - p. 193-203 , 2023

Link: https://doi.org/10.1016/..

10

Genetic-Guided Pharmacotherapy for Atrial Fibrillation: A S..:

Kamil, Ahmad Amir ; Lim, Ka Keat ; Koleva-Kolarova, Rositsa...
Value in Health. 25 (2022) 3 - p. 461-472 , 2022

Link: https://doi.org/10.1016/..

11

Can upfront DPYD extended variant testing reduce toxicity a..:

Tsiachristas, Apostolos ; Vallance, Grant ; Koleva-Kolarova, Rositsa...
BMC Cancer. 22 (2022) 1 - p. , 2022

Link: https://doi.org/10.1186/..

12

A Comparison of the Content and Consistency of Methodologic..:

Lim, Ka Keat ; Koleva-Kolarova, Rositsa ; Fox-Rushby, Julia
PharmacoEconomics. 40 (2022) 10 - p. 989-1003 , 2022

Link: https://doi.org/10.1007/..

13

The Net Benefit of Personalized Medicine: A Systematic Lite..:

Vellekoop, Heleen ; Versteegh, Matthijs ; Huygens, Simone...
Value in Health. 25 (2022) 8 - p. 1428-1438 , 2022

Link: https://doi.org/10.1016/..

14

Financing and Reimbursement Models for Personalised Medicin..:

Koleva-Kolarova, Rositsa ; Buchanan, James ; Vellekoop, Heleen...
Applied Health Economics and Health Policy. 20 (2022) 4 - p. 501-524 , 2022

Link: https://doi.org/10.1007/..

15

Guidance for the Harmonisation and Improvement of Economic ..:

Vellekoop, Heleen ; Huygens, Simone ; Versteegh, Matthijs...
PharmacoEconomics. 39 (2021) 7 - p. 771-788 , 2021

Link: https://doi.org/10.1007/..